Stage III Colon Cancer AJCC v8
我们是谁
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
SX-682和Nivolumab治疗RAS突变、MSS不可切除或转移性结直肠癌的STOPTRAFFIC-1试验